{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T10:23:45Z","timestamp":1743675825031},"reference-count":58,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["medical-hypotheses.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Hypotheses"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1016\/j.mehy.2014.09.032","type":"journal-article","created":{"date-parts":[[2014,10,13]],"date-time":"2014-10-13T18:49:52Z","timestamp":1413226192000},"page":"747-750","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"83","author":[{"given":"Silvia","family":"Hoirisch-Clapauch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonio Egidio","family":"Nardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mehy.2014.09.032_b0005","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1111\/j.1538-7836.2005.01425.x","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"L\u00e4mmle","year":"2005","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2014.09.032_b0010","first-page":"407","article-title":"Recent advances in thrombotic thrombocytopenic purpura","author":"Sadler","year":"2004","journal-title":"ASH Educ Program Book"},{"key":"10.1016\/j.mehy.2014.09.032_b0015","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1182\/blood.V98.6.1662","article-title":"Purification of human von Willebrand factor cleaving protease and its identification as a new member of the metalloproteinase family","volume":"98","author":"Fujikawa","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2014.09.032_b0020","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2003-01-0193","article-title":"ADAMTS13 activity in thrombotic thrombocytopenic purpura\u2013hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients","volume":"102","author":"Vesely","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2014.09.032_b0025","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.113.006727","article-title":"Plasmin cleavage of von Willebrand factor as an emergency bypass for ADAMTS13 deficiency in thrombotic microangiopathy","volume":"129","author":"Tersteeg","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2014.09.032_b0030","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1016\/j.thromres.2011.11.021","article-title":"Modulation of the von Willebrand factor-dependent platelet adhesion through alternative proteolytic pathways","volume":"129","author":"Wohner","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.mehy.2014.09.032_b0035","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/jb\/mvs066","article-title":"Binding of von Willebrand factor cleaving protease ADAMTS13 to Lys-plasmin(ogen)","volume":"152","author":"Shin","year":"2012","journal-title":"J Biochem"},{"key":"10.1016\/j.mehy.2014.09.032_b0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1681\/ASN.2013050453","article-title":"Comprehensive genetic analysis of complement and coagulation genes in atypical hemolytic uremic syndrome","volume":"25","author":"Bu","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.mehy.2014.09.032_b0045","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1538-7836.2007.02776.x","article-title":"Plasminogen deficiency","volume":"5","author":"Schuster","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2014.09.032_b0050","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2014.09.032_b0055","doi-asserted-by":"crossref","first-page":"P5498","DOI":"10.1093\/eurheartj\/eht310.P5498","article-title":"Role of plasminogen activator inhibitor and free fatty acids in diagnosis of insulin resistance in patients with myocardial infarction","volume":"34","author":"Gruzdeva","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.mehy.2014.09.032_b0060","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ajh.21881","article-title":"Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura","volume":"86","author":"Cataland","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mehy.2014.09.032_b0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neulet.2012.03.002","article-title":"ADAMTS-13 is produced by glial cells and upregulated after spinal cord injury","volume":"517","author":"Tauchi","year":"2012","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.mehy.2014.09.032_b0070","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1212\/01.wnl.0000269668.08747.78","article-title":"Tissue plasminogen activator. Beyond thrombolysis","volume":"69","author":"Benarroch","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.mehy.2014.09.032_b0075","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1160\/TH04-12-0838","article-title":"Tissue plasminogen activator in central nervous system physiology and pathology","volume":"93","author":"Melchor","year":"2005","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.mehy.2014.09.032_b0080","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1038\/nn1971","article-title":"New insights into BDNF function in depression and anxiety","volume":"10","author":"Martinowich","year":"2007","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.mehy.2014.09.032_b0085","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1097\/FPC.0b013e328308bbc0","article-title":"Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response","volume":"18","author":"Tsai","year":"2008","journal-title":"Pharmacogenet Genomics"},{"key":"10.1016\/j.mehy.2014.09.032_b0090","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/nrn1726","article-title":"The yin and yang of neurotrophin action","volume":"6","author":"Lu","year":"2005","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.mehy.2014.09.032_b0095","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1210\/me.2008-0421","article-title":"Insulin acts through FOXO3a to activate transcription of plasminogen activator inhibitor type 1","volume":"23","author":"Jag","year":"2009","journal-title":"Mol Endocrinol"},{"key":"10.1016\/j.mehy.2014.09.032_b0100","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1161\/01.CIR.99.23.3050","article-title":"Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance","volume":"99","author":"Zhu","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.mehy.2014.09.032_b0105","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1055\/s-0033-1337988","article-title":"Mechanism of insulin resistance in normal pregnancy","volume":"45","author":"Hodson","year":"2013","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.mehy.2014.09.032_b0110","doi-asserted-by":"crossref","first-page":"380","DOI":"10.2337\/diab.34.4.380","article-title":"Insulin action during pregnancy. Studies with the euglycemic clamp technique","volume":"34","author":"Ryan","year":"1985","journal-title":"Diabetes"},{"key":"10.1016\/j.mehy.2014.09.032_b0115","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1038\/nri3071","article-title":"Macrophage-mediated inflammation in metabolic disease","volume":"11","author":"Chawla","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.mehy.2014.09.032_b0120","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","article-title":"Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction","volume":"59","author":"Briones","year":"2012","journal-title":"Hypertension"},{"key":"10.1016\/j.mehy.2014.09.032_b0125","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1182\/blood-2013-11-538900","article-title":"Pregnancy outcomes following recovery from acquired thrombotic thrombocytopenic purpura","volume":"123","author":"Jiang","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.mehy.2014.09.032_b0130","doi-asserted-by":"crossref","first-page":"e56907","DOI":"10.1371\/journal.pone.0056907","article-title":"Association of plasminogen activator inhibitor-type 1 (-675 4G\/5G) polymorphism with pre-eclampsia: systematic review","volume":"8","author":"Morgan","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.mehy.2014.09.032_b0135","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/ajh.2011.164","article-title":"Hyperinsulinemia increases placenta endothelin-converting enzyme-1 expression in trophoblasts","volume":"25","author":"Khamaisi","year":"2012","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.mehy.2014.09.032_b0140","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/bmj.38313.513310.F71","article-title":"Insulin resistance and depression: cross sectional study","volume":"330","author":"Timonen","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.mehy.2014.09.032_b0145","doi-asserted-by":"crossref","first-page":"859","DOI":"10.3233\/JAD-2009-0975","article-title":"Vascular factors in diabetes and Alzheimer\u2019s disease","volume":"16","author":"Taguchi","year":"2009","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.mehy.2014.09.032_b0150","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1017\/S1461145711000368","article-title":"Subchronic treatment with aldosterone induces depression-like behaviours and gene expression changes relevant to major depressive disorder","volume":"15","author":"Hlavacova","year":"2012","journal-title":"Int J Neuropsychopharmacol"},{"key":"10.1016\/j.mehy.2014.09.032_b0155","doi-asserted-by":"crossref","first-page":"3782","DOI":"10.1073\/pnas.0804037106","article-title":"Aldosterone activates endothelial exocytosis","volume":"106","author":"Jeong","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mehy.2014.09.032_b0160","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.freeradbiomed.2009.11.020","article-title":"Formation of methionine sulfoxide by peroxynitrite at position 1606 of von Willebrand factor inhibits its cleavage by ADAMTS-13: a new prothrombotic mechanism in diseases associated with oxidative stress","volume":"48","author":"Lancellotti","year":"2010","journal-title":"Free Radic Biol Med"},{"key":"10.1016\/j.mehy.2014.09.032_b0165","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1111\/j.1538-7836.2006.01949.x","article-title":"Von Willebrand factor, endothelial dysfunction, and cardiovascular disease","volume":"4","author":"Vischer","year":"2006","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.mehy.2014.09.032_b0170","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1749-6632.2012.06620.x","article-title":"Endocrine, metabolic, and immunologic components of HIV infection","volume":"1262","author":"Norbiato","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.mehy.2014.09.032_b0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.yfrne.2008.10.001","article-title":"Interleukin-1 (IL-1): a central regulator of stress responses","volume":"30","author":"Goshen","year":"2009","journal-title":"Front Neuroendocrinol"},{"key":"10.1016\/j.mehy.2014.09.032_b0180","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/j.1365-2265.2010.03794.x","article-title":"Subclinical hypercortisolism: correlation between biochemical diagnostic criteria and clinical aspects","volume":"73","author":"Morelli","year":"2010","journal-title":"Clin Endocrinol"},{"key":"10.1016\/j.mehy.2014.09.032_b0185","doi-asserted-by":"crossref","first-page":"14299","DOI":"10.1074\/jbc.M005363200","article-title":"Heterodimerization of mineralocorticoid and glucocorticoid receptors at a novel negative response element of the 5-HT1A receptor gene","volume":"276","author":"Ou","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2014.09.032_b0190","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.pneurobio.2009.01.009","article-title":"5-HT1A receptor function in major depressive disorder","volume":"88","author":"Savitz","year":"2009","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.mehy.2014.09.032_b0195","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/BF03345709","article-title":"Blood coagulation and fibrinolysis in patients with Cushing\u2019s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels","volume":"32","author":"Erem","year":"2009","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.mehy.2014.09.032_b0200","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1210\/jc.2011-2753","article-title":"The hypercoagulable state in Cushing\u2019s disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy","volume":"97","author":"Van der Pas","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.mehy.2014.09.032_b0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.cardiores.2004.07.006","article-title":"Does altered glucocorticoid homeostasis increase cardiovascular risk?","volume":"64","author":"Girod","year":"2004","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.mehy.2014.09.032_b0210","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/00001721-199904000-00006","article-title":"Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing\u2019s syndrome","volume":"10","author":"Casonato","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.mehy.2014.09.032_b0215","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1097\/MBC.0b013e3283548dfc","article-title":"Effect of glucocorticoids on von Willebrand factor levels and its correlation with von Willebrand factor gene promoter polymorphism","volume":"23","author":"Chopra","year":"2012","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.mehy.2014.09.032_b0220","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10067-011-1922-z","article-title":"Cognitive impairment in antiphospholipid syndrome: evidence from animal models","volume":"31","author":"Appenzeller","year":"2012","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.mehy.2014.09.032_b0225","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s11926-009-0075-4","article-title":"Impaired fibrinolysis in the antiphospholipid syndrome","volume":"12","author":"Krone","year":"2010","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.mehy.2014.09.032_b0230","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1136\/ard.2010.130476","article-title":"EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs","volume":"69","author":"Bertsias","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.mehy.2014.09.032_b0235","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.transci.2006.02.001","article-title":"Thrombotic thrombocytopenic purpura and systemic lupus erythematosus \u2013 distinct entities or overlapping syndromes?","volume":"34","author":"Cheung","year":"2006","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.mehy.2014.09.032_b0240","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1177\/096120339900800613","article-title":"Relapsing catastrophic antiphospholipid antibody syndrome: a mimic for thrombotic thrombocytopenic purpura?","volume":"8","author":"Cerveny","year":"1999","journal-title":"Lupus"},{"key":"10.1016\/j.mehy.2014.09.032_b0245","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1038\/ki.2008.609","article-title":"The thrombotic thrombocytopenic purpura and hemolytic uremic syndromes: overview of pathogenesis (experience of the Oklahoma TTP-HUS Registry, 1989\u20132007)","volume":"75","author":"George","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.mehy.2014.09.032_b0250","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2141.2012.09167.x","article-title":"Guidelines on the diagnosis and management of thrombotic thrombocytopenic purpura and other thrombotic microangiopathies","volume":"158","author":"Scully","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.mehy.2014.09.032_b0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/jac\/dki414","article-title":"Thrombotic-thrombocytopenic purpura following malaria prophylaxis with mefloquine","volume":"57","author":"Fiaccadori","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mehy.2014.09.032_b0260","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s11255-010-9755-2","article-title":"Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient","volume":"43","author":"Yilmaz","year":"2011","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.mehy.2014.09.032_b0265","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1097\/01.tp.0000232286.22319.e0","article-title":"Subclinical inflammation and prothrombotic state in heart transplant recipients: impact of cyclosporin microemulsion vs. tacrolimus","volume":"82","author":"White","year":"2006","journal-title":"Transplantation"},{"key":"10.1016\/j.mehy.2014.09.032_b0270","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2013.07.004","article-title":"Treatment with everolimus is associated with a procoagulant state","volume":"132","author":"Baas","year":"2013","journal-title":"Thromb Res"},{"key":"10.1016\/j.mehy.2014.09.032_b0275","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/ajh.2830500404","article-title":"Hemostatic abnormalities and increased vascular endothelial cell markers in patients with red cell fragmentation syndrome induced by mitomycin C","volume":"50","author":"Nagaya","year":"1995","journal-title":"Am J Hematol"},{"key":"10.1016\/j.mehy.2014.09.032_b0280","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1091\/mbc.E12-04-0306","article-title":"Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer","volume":"24","author":"Asuthkar","year":"2013","journal-title":"Mol Biol Cell"},{"key":"10.1016\/j.mehy.2014.09.032_b0285","doi-asserted-by":"crossref","first-page":"15454","DOI":"10.1016\/S0021-9258(19)37610-0","article-title":"Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)","volume":"263","author":"Declerck","year":"1988","journal-title":"J Biol Chem"},{"key":"10.1016\/j.mehy.2014.09.032_b0290","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1160\/TH12-10-0771","article-title":"The effect of different hormonal contraceptives on plasma levels of free protein S and free TFPI","volume":"109","author":"Raps","year":"2013","journal-title":"Thromb Haemost"}],"container-title":["Medical Hypotheses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714003582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0306987714003582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T21:35:14Z","timestamp":1717450514000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0306987714003582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12]]},"references-count":58,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["S0306987714003582"],"URL":"https:\/\/doi.org\/10.1016\/j.mehy.2014.09.032","relation":{},"ISSN":["0306-9877"],"issn-type":[{"value":"0306-9877","type":"print"}],"subject":[],"published":{"date-parts":[[2014,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A role for tissue plasminogen activator in thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Medical Hypotheses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mehy.2014.09.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}